Literature DB >> 17118297

Impact of biologic agents on infectious diseases.

Lesley Ann Saketkoo1, Luis R Espinoza.   

Abstract

Until recently, inflammatory diseases, collagen vascular diseases, inflammatory bowel diseases, and multiple sclerosis were met with a limited offering for treatment. The introduction of biologic agents has revolutionized the approach to these diseases, offering many patients freedom from disease activity staving off resultant destruction to organs and joints with marked improvement in quality of life and disability. This article focuses on the development of serious infections associated with the use of biologic agents. Presented is a synthesis of case series, reports, and systematic reviews to elucidate implicated pathogens and clinical presentations in patients being treated with biologic agents and to form a cursory backbone for prevention and treatment strategies to which clinicians prescribing these agents or encountering patients already on these agents can readily refer. Maintenance of a high index of suspicion is imperative for the prevention and appropriate treatment of serious life-threatening infections in these patients.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17118297     DOI: 10.1016/j.idc.2006.09.001

Source DB:  PubMed          Journal:  Infect Dis Clin North Am        ISSN: 0891-5520            Impact factor:   5.982


  4 in total

1.  Fatal group A Streptococcus purpura fulminans in a child receiving TNF-α blocker.

Authors:  Christian Renaud; Philippe Ovetchkine; Patricia Bortolozzi; Claire Saint-Cyr; Bruce Tapiero
Journal:  Eur J Pediatr       Date:  2010-11-10       Impact factor: 3.183

2.  Past hepatitis B virus infection in rheumatoid arthritis patients receiving biological and/or nonbiological disease-modifying antirheumatic drugs.

Authors:  Shunsuke Mori
Journal:  Mod Rheumatol       Date:  2011-04-29       Impact factor: 3.023

3.  Efficacy and safety of anakinra for the treatment of rheumatoid arthritis: an update of the Oregon Drug Effectiveness Review Project.

Authors:  Kylie Thaler; Divya V Chandiramani; Richard A Hansen; Gerald Gartlehner
Journal:  Biologics       Date:  2009-12-29

4.  Therapeutic challenges of psoriasis in the HIV-infected patient: A case report.

Authors:  Manuela Arbune; Anca-Adriana Arbune; Elena Niculet; Lucretia Anghel; Silvia Fotea; Alin Laurentiu Tatu
Journal:  Exp Ther Med       Date:  2021-12-28       Impact factor: 2.447

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.